ENDRA Life Sciences Inc. (NASDAQ:NDRA) is down 6.70% intraday at $5.85 as a low-float, thin-volume session sees speculative holders exit the TAEUS ultrasound liver fat assessment platform in the absence of positive newsflow.

Key Highlights

• ENDRA Life Sciences is down 6.70% intraday at $5.85, consistent with a pattern of opening strength followed by sharp reversal characteristic of low-float medical device names without fresh catalysts.

• The TAEUS ultrasound-based system assesses liver fat non-invasively for NASH-related diagnosis, approved in multiple international markets with commercial revenue still nascent.

• Very low float and thin average daily volume mean speculative holders exit quickly when positive newsflow is absent.

• At $5.85 the stock is within its recent trading range; the intraday fade from an opening gain is a technically weak signal.

Low-Float Medical Device Reversal Pattern

ENDRA Life Sciences Inc. (NASDAQ:NDRA), an Ann Arbor, Michigan-based medical device company developing its TAEUS ultrasound-based liver fat assessment system for non-invasive diagnosis of fatty liver disease and NASH-related conditions, is down 6.70% intraday at $5.85. The session opened with strength before reversing sharply, a pattern characteristic of low-float medical device names in the absence of fresh positive catalyst. Very low float and thin average daily volume mean that speculative holders exit quickly when there is nothing to sustain the move.

No specific negative catalyst has been confirmed today. ENDRA's stock has been volatile around TAEUS commercial milestones, and sessions without positive newsflow tend to see speculative positioning unwind rapidly.

TAEUS Platform and Commercial Revenue Context

The TAEUS system uses calibrated ultrasound to quantify liver fat content non-invasively, offering an alternative to more invasive biopsy or MRI-based assessment methods for fatty liver disease and NASH evaluation. The system has received approval for use in multiple international markets, and ENDRA has been working to drive physician adoption in clinical settings.

Commercial revenue remains nascent relative to the company's cost base, reflecting the slow adoption cycle typical of novel diagnostic technologies requiring clinical workflow integration and reimbursement pathway development. At $5.85, the stock is within its recent trading range, but the pattern of an opening gain followed by a sharp intraday fade is a technically weak signal suggesting the near-term risk remains skewed to the downside in the absence of a positive data readout or commercial milestone.